{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:58:57Z","timestamp":1790373537496,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Africa"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lanafr.2026.100028","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:32:46Z","timestamp":1773703966000},"page":"100028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Virologic outcomes among people living with HIV on dolutegravir-based antiretroviral therapy in Kenya, 2018\u20132024: a comparison retrospective longitudinal analysis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1050-7361","authenticated-orcid":false,"given":"Helen M","family":"Chun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri L.","family":"Pals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7996-9908","authenticated-orcid":false,"given":"Mary","family":"Gikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pacific","family":"Akinyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Odhiambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-2643","authenticated-orcid":false,"given":"Emilio","family":"Dirlikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Appolonia","family":"Aoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freda","family":"Kinoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzuna","family":"Moturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Mecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Njigua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junghae","family":"Muthoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Basiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Masamaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanafr.2026.100028_bib1","article-title":"Consolidated guidelines on HIV prevention, testing, service delivery and monitoring: recommendations for a public health approach","volume":"592","year":"2021","journal-title":"World Health Organ"},{"key":"10.1016\/j.lanafr.2026.100028_bib2","year":"2018"},{"issue":"10","key":"10.1016\/j.lanafr.2026.100028_bib3","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.lanafr.2026.100028_bib4","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open-label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.lanafr.2026.100028_bib5","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","article-title":"Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study","volume":"10","author":"Dorward","year":"2023","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.lanafr.2026.100028_bib6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-Based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Kouanfack","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lanafr.2026.100028_bib7","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.lanafr.2026.100028_bib8","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study","volume":"9","author":"Schramm","year":"2022","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.lanafr.2026.100028_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae261","article-title":"Virologic failure and drug resistance after programmatic switching to Dolutegravir-based first-line antiretroviral therapy in Malawi and Zambia","volume":"80","author":"Skrivankova","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.lanafr.2026.100028_bib10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/cid\/ciab1006","article-title":"Viral load status before switching to Dolutegravir-Containing antiretroviral therapy and associations with human immunodeficiency virus treatment outcomes in Sub-Saharan Africa","volume":"75","author":"Romo","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.lanafr.2026.100028_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/hiv.13189","article-title":"Viral suppression after transition from non-nucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study)","volume":"23","author":"Brown","year":"2022","journal-title":"HIV Med"},{"issue":"5","key":"10.1016\/j.lanafr.2026.100028_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232419","article-title":"High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: a mixed-methods prospective cohort study","volume":"15","author":"Nabitaka","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lanafr.2026.100028_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae260","article-title":"Population effectiveness of Dolutegravir implementation in Uganda: a prospective observational cohort study (DISCO), 48-Week results","volume":"230","author":"McCluskey","year":"2024","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.lanafr.2026.100028_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAI.0000000000003065","article-title":"Virologic impact of the dolutegravir transition: prospective results from the multinational African Cohort Study","volume":"91","author":"Esber","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.lanafr.2026.100028_bib15","series-title":"R: a language and environment for statistical computing","year":"2021"},{"issue":"1","key":"10.1016\/j.lanafr.2026.100028_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Software"},{"issue":"4","key":"10.1016\/j.lanafr.2026.100028_bib17","doi-asserted-by":"crossref","first-page":"E1008","DOI":"10.1093\/cid\/ciab086","article-title":"Participants on Dolutegravir resuppress human immunodeficiency virus RNA after virologic failure: updated data from the ADVANCE trial","volume":"73","author":"Pepperrell","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.lanafr.2026.100028_bib18","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/S2352-3018(24)00155-3","article-title":"Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial","volume":"12","author":"White","year":"2025","journal-title":"Lancet HIV"},{"issue":"Suppl 2","key":"10.1016\/j.lanafr.2026.100028_bib19","article-title":"Adherence, resistance, and viral suppression on dolutegravir in Sub-Saharan Africa: implications for the TLD era","volume":"35","author":"McCluskey","year":"2021","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.lanafr.2026.100028_bib20","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/ciad390","article-title":"Two-Year outcomes of treatment-experienced adults after programmatic transitioning to Dolutegravir: longitudinal data from the VICONEL human immunodeficiency virus cohort in Lesotho","volume":"77","author":"Tschumi","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanafr.2026.100028_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijid.2021.02.045","article-title":"Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy","volume":"105","author":"Chen","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.lanafr.2026.100028_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study","volume":"18","author":"Hermans","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.lanafr.2026.100028_bib23","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1016\/S2214-109X(22)00413-2","article-title":"Low-level viraemia among people living with HIV in Nigeria: a retrospective longitudinal cohort study","volume":"10","author":"Chun","year":"2022","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.lanafr.2026.100028_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102166","article-title":"Retrospective longitudinal analysis of low-level viremia among HIV-1-infected adults on antiretroviral therapy in Kenya","volume":"63","author":"Aoko","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"8","key":"10.1016\/j.lanafr.2026.100028_bib25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure","volume":"28","author":"Swenson","year":"2014","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.lanafr.2026.100028_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"}],"container-title":["The Lancet Regional Health - Africa"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305050112600009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305050112600009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:04:48Z","timestamp":1790370288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305050112600009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S305050112600009X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanafr.2026.100028","relation":{},"ISSN":["3050-5011"],"issn-type":[{"value":"3050-5011","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virologic outcomes among people living with HIV on dolutegravir-based antiretroviral therapy in Kenya, 2018\u20132024: a comparison retrospective longitudinal analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Africa","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanafr.2026.100028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100028"}}